Contraceptive Efficacy of Oral and Transdermal Hormones When Co-Administered With Protease Inhibitors in HIV-1-Infected Women: Pharmacokinetic Results of ACTG Trial A5188

Mary Vogler(Northwestern University), Susan E. Cohn(Brigham and Women's Hospital), Karin L. Klingman(National Institutes of Health), Heather Watts(Eunice Kennedy Shriver National Institute of Child Health and Human Development), Jeong-Gun Park(Frontier Science & Technology Research Foundation, Inc.), Lori Kamemoto(University of Hawaiʻi at Mānoa), Kristine B. Patterson(University of North Carolina at Chapel Hill), Francesca Aweeka(University of California, San Francisco)
JAIDS Journal of Acquired Immune Deficiency Syndromes
September 14, 2010
10.1097/qai.0b013e3181eb5ff5
Cited by 115

Related Papers

Tryptophan Catabolism by Indoleamine 2,3-Dioxygenase 1 Alters the Balance of T <sub>H</sub> 17 to Regulatory T Cells in HIV Disease
|Science Translational Medicine|2010|514
Penetration of Tenofovir and Emtricitabine in Mucosal Tissues: Implications for Prevention of HIV-1 Transmission
|Science Translational Medicine|2011|352
Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention
|New England Journal of Medicine|2016|348
A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine
|The Journal of Infectious Diseases|2016|303
Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms
|Cell Reports|2021|266